
The State Street SPDR S&P Telecom ETF aims to replicate the total return performance of the S&P Telecom Select Industry Index, before accounting for fees and expenses. It offers investors focused exposure to the telecommunications segment of the S&P TMI, covering distinct sub-industries like Alternative Carriers, Communications Equipment, Integrated Telecommunication Services, and Wireless Telecommunication Services. The fund tracks a modified equal-weighted index, which fosters balanced industry representation across large, mid, and small-capitalization stocks. This structure enables…
Is XTL's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

The State Street SPDR S&P Telecom ETF (XTL) was launched on 01/26/2011, and is a smart beta exchange traded fund designed to offer broad exposure to the Communication Services ETFs category of the market.

SPDR S&P Telecom ETF (XTL) offers diversified exposure to U.S. telecom and communications equipment, benefiting from AI-driven network demand and sector consolidation. XTL has delivered robust performance, with 50% annual and 200% three-year returns, but recent appreciation tempers short-term upside. Key growth drivers include AI data center expansion, fiber and 5G investments, and satellite-terrestrial integration, while valuation stands at 16.7x P/E.

Making its debut on 01/26/2011, smart beta exchange traded fund State Street SPDR S&P Telecom ETF (XTL) provides investors broad exposure to the Communication Services ETFs category of the market.

State Street SPDR S&P Telecom ETF earns a strong buy rating, driven by 80% twelve-month price returns and robust AI-powered demand trends. XTL's portfolio is concentrated in high-growth communication equipment and alternative carrier industries, offsetting weakness in integrated and wireless telecom holdings. Top holdings like Viasat, Extreme Networks, and Ciena have delivered triple-digit or near-triple-digit returns, benefiting from secular AI and data center demand.

expands its IP portfolio to clinical-stage biopharmaceutical assets XTL Biopharmaceuticals (XTL) Completes the Acquisition of Psyga Bio and Establishes Psychedelic Biotechnology Platform At a historic juncture and with unprecedented regulatory tailwinds in the US, XTL completes its strategic transformation and becomes a dedicated company in the field of global psychedelic medicine; operations will focus on an advanced clinical pipeline, a licensed GMP manufacturing facility, and a unique intellectual property (IP) library. HERZLIYA, ISRAEL, June 30, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd.